TTR and amyloidosis: These data represent the natural history of cardiac ATTR, because nearly all patients with amyloidosis in the UK are evaluated at the National Amyloidosis Centre, and tafamidis, the only disease-modifying therapy approved for ATTR-CM, is widely unavailable in the UK due mainly to its high cost [201].